Develops precision, adaptable bacteriophage-based therapies to treat chronic, hard-to-treat orphan bacterial infections such as Mycobacterium abscessus complex pulmonary disease. Disease-agnostic therapeutic platform designed to deliver safe, effective phage treatments for a broad range of bacterial infections.